266 related articles for article (PubMed ID: 32363479)
1. Gemcitabine and cisplatin versus docetaxel and cisplatin as induction chemotherapy followed by concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma from non-endemic area of China.
Zang J; Xu M; Li C; Zhao L; Luo S; Wang J; Shi M
J Cancer Res Clin Oncol; 2020 Sep; 146(9):2369-2378. PubMed ID: 32363479
[TBL] [Abstract][Full Text] [Related]
2. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
Wei Z; Zhang Z; Luo J; Li N; Peng X
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
[TBL] [Abstract][Full Text] [Related]
3. Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma.
Zhao L; Xu M; Jiang W; Pan H; Zang J; Luo S; Wang J; Zhou Y; Shi M
Oncotarget; 2017 Jan; 8(4):6763-6774. PubMed ID: 28036270
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of gemcitabine plus cisplatin versus docetaxel, cisplatin and fluorouracil for induction chemotherapy of locoregionally advanced nasopharyngeal carcinoma.
Wu Q; Liao W; Huang J; Zhang P; Zhang N; Li Q
Oral Oncol; 2020 Apr; 103():104588. PubMed ID: 32070923
[TBL] [Abstract][Full Text] [Related]
5. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial.
Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY
Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966
[TBL] [Abstract][Full Text] [Related]
6. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis.
Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ
Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402
[TBL] [Abstract][Full Text] [Related]
7. Comparison of GP and TPF induction chemotherapy for locally advanced nasopharyngeal carcinoma.
Zhu J; Duan B; Shi H; Li Y; Ai P; Tian J; Chen N
Oral Oncol; 2019 Oct; 97():37-43. PubMed ID: 31421469
[TBL] [Abstract][Full Text] [Related]
8. Comparison of efficacy and safety of three induction chemotherapy regimens with gemcitabine plus cisplatin (GP), cisplatin plus fluorouracil (PF) and cisplatin plus capecitabine (PX) for locoregionally advanced previously untreated nasopharyngeal carcinoma: A pooled analysis of two prospective studies.
Chan SK; Chan SY; Tong CC; Lam KO; Kwong DL; Leung TW; Luk MY; Lee AW; Choi HC; Lee VH
Oral Oncol; 2021 Mar; 114():105158. PubMed ID: 33508707
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine combined with cisplatin vs. taxane, cisplatin, and fluorouracil in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective case-control study.
Huang YM; Qiao SQ; Lu L; Chen WP; Li SL; Qi CH
Eur Rev Med Pharmacol Sci; 2020 Jul; 24(14):7655-7663. PubMed ID: 32744691
[TBL] [Abstract][Full Text] [Related]
10. A meta-analysis comparing the efficacy and safety of gemcitabine plus cisplatin induction chemotherapy in patients with locoregionally advanced NPC.
Xiao L; Kang W; Liao J; Li Y
Eur Arch Otorhinolaryngol; 2022 May; 279(5):2441-2450. PubMed ID: 34410469
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: A phase III multicentre randomised controlled trial.
Cao SM; Yang Q; Guo L; Mai HQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Qiu F; Sun R; Chen QY; Huang PY; Luo DH; Hua YJ; Wu YS; Lv X; Wang L; Xia WX; Tang LQ; Ye YF; Chen MY; Guo X; Hong MH
Eur J Cancer; 2017 Apr; 75():14-23. PubMed ID: 28214653
[TBL] [Abstract][Full Text] [Related]
12. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study.
Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W
Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907
[TBL] [Abstract][Full Text] [Related]
13. Assessment of Concurrent Chemoradiotherapy plus Induction Chemotherapy in Advanced Nasopharyngeal Carcinoma: Cisplatin, Fluorouracil, and Docetaxel versus Gemcitabine and Cisplatin.
Zeng Z; Yan RN; Tu L; Wang YY; Chen PR; Luo F; Liu L
Sci Rep; 2018 Oct; 8(1):15581. PubMed ID: 30348970
[TBL] [Abstract][Full Text] [Related]
14. Survival benefit of adding docetaxel, cisplatin, and 5-fluorouracil induction chemotherapy to concurrent chemoradiotherapy for locally advanced nasopharyngeal carcinoma with nodal Stage N2-3.
Kawahira M; Yokota T; Hamauchi S; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H
Jpn J Clin Oncol; 2017 Aug; 47(8):705-712. PubMed ID: 28431119
[TBL] [Abstract][Full Text] [Related]
15. Tumor Volume Reduction After Gemcitabine Plus Cisplatin Induction Chemotherapy in Locally Advanced Nasopharyngeal Cancer: Comparison with Paclitaxel and Cisplatin Regimens.
Zheng L; Liao W; Xu P; Li B; Wen H; Zhang S
Med Sci Monit; 2018 Nov; 24():8001-8008. PubMed ID: 30406770
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma.
Zhang Y; Chen L; Hu GQ; Zhang N; Zhu XD; Yang KY; Jin F; Shi M; Chen YP; Hu WH; Cheng ZB; Wang SY; Tian Y; Wang XC; Sun Y; Li JG; Li WF; Li YH; Tang LL; Mao YP; Zhou GQ; Sun R; Liu X; Guo R; Long GX; Liang SQ; Li L; Huang J; Long JH; Zang J; Liu QD; Zou L; Su QF; Zheng BM; Xiao Y; Guo Y; Han F; Mo HY; Lv JW; Du XJ; Xu C; Liu N; Li YQ; Chua MLK; Xie FY; Sun Y; Ma J
N Engl J Med; 2019 Sep; 381(12):1124-1135. PubMed ID: 31150573
[TBL] [Abstract][Full Text] [Related]
17. Gemcitabine plus cisplatin versus fluorouracil plus cisplatin as a first-line concurrent chemotherapy regimen in nasopharyngeal carcinoma: a prospective, multi-institution, randomized controlled phase II study.
Kong XY; Lu JX; Yu XW; Zhang J; Xu QL; Zhang RJ; Mi JL; Liao SF; Fan JF; Qin XL; Yao DC; Tang HY; Jiang W
Cancer Chemother Pharmacol; 2019 Jul; 84(1):155-161. PubMed ID: 31087135
[TBL] [Abstract][Full Text] [Related]
18. The safety and efficacy of gemcitabine and cisplatin (GP)-based induction chemotherapy plus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
Tang M; Jia Z; Zhang J
Eur Arch Otorhinolaryngol; 2022 Mar; 279(3):1561-1572. PubMed ID: 34259896
[TBL] [Abstract][Full Text] [Related]
19. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
[TBL] [Abstract][Full Text] [Related]
20. Induction gemcitabine and cisplatin in locoregionally advanced nasopharyngeal carcinoma.
Zhang Y; Sun Y; Ma J
Cancer Commun (Lond); 2019 Jun; 39(1):39. PubMed ID: 31238975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
